Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Capturing the Opportunity: The convergence of the booming GLP-1 market and the growing demand for behavior change solutions creates a once-in-a-lifetime business opportunity for digital health companies that offer behavioral change support
The thing is, there are things inherent to our metabolic makeup that make that a very, very difficult process, even compared to the general population. Meet the experts: Kerry Krauss , MD, is an OB-GYN and Natural Cycles advisor
Want to try a spin class
demonstrated that febuxostat treatment to reduce serum uric acid levels tended to reduce renal functional deterioration in patients with both CKD and hyperuricemia
(23 Sep, 2025)
Treatment of GLP-1 in combination with exendin-4 showed additive action on the generation of cAMP
US$ 21.88
US$ 22.85
US$ 27.97
US$ 22.08
US$ 21.22
